Group 1 - Beijing Junzheng adjusted management expenses by 11.44 million yuan, increasing net profit by the same amount [1] - Ningbo Energy's subsidiary plans to publicly transfer 15% equity of Lingfeng Energy at a base price of 16.06 million yuan [1] - Dongjiang Environmental's subsidiary was fined 2.02 million yuan for tax evasion [1][2] Group 2 - AVIC's subsidiary Harbin Aircraft Industry Group plans to absorb and merge with Harbin Hafei Aviation, increasing registered capital to 3.038 billion yuan [3] - Dongfang Ocean's shareholder plans to reduce holdings by up to 3% of total shares [4] - Xinghui Entertainment's controlling shareholder plans to reduce holdings by up to 2.9% of total shares [6] Group 3 - Kaineng Health plans to acquire 100% equity of four subsidiaries for 204 million yuan [8] - Suoao Sensor's controlling shareholder changed to Zhongchuang Innovation [9] - Shanghai Port Bay reported that its commercial aerospace and perovskite solar business accounts for less than 1% of revenue [10] Group 4 - Zhonghuan Environmental's specific shareholder plans to reduce holdings by up to 2.37% of total shares [11] - Xinlaifu's asset management plan intends to reduce 874,300 shares [12] - Guangdian Measurement plans to invest 800 million yuan to build a testing base [13] Group 5 - Modern Investment plans to invest 1.04 billion yuan to establish a smart logistics company [14] - Gaole Co.'s major shareholder is planning a control change, leading to stock suspension [16] - Weiling Co.'s major shareholder is planning a control change, leading to stock suspension [18] Group 6 - Igor plans to issue H-shares and apply for listing on the Hong Kong Stock Exchange [20] - Huanrui Century's shareholder sold 7.26 million shares due to judicial enforcement [21] - Jinhua Co.'s controlling shareholder plans to acquire 5.77% of company shares at 9.15 yuan per share [22] Group 7 - Wireless Media's four shareholders plan to reduce holdings by up to 4.7% of total shares [24] - CATL's shareholder completed the transfer of 10% of shares for approximately 17.16 billion yuan [26] - *ST Lian Stone entered the restructuring phase, with potential downward adjustment of stock price [28]

金花股份表示，本次协议转让系公司控股股东、实际控制人邢博越及其一致行动人之间内部转让，其合 计持股比例、数量和表决权未发生变化。 北京商报讯（记者 丁宁）11月25日，金花股份（600080）发布公告称，公司控股股东、实际控制人邢 博越及其一致行动人杜玲、杨蓓签订了《股权转让协议书》，杜玲、杨蓓拟通过协议转让的方式分别将 各自持有的公司1097.42万股（占公司总股本的2.94%）、1054.56万股（占公司总股本的2.83%），合计 2151.98万股（占公司总股本的5.77%）转让予邢博越。 ...

格隆汇11月24日丨金花股份（维权）(600080.SH)公布，2025年11月24日，公司控股股东、实际控制人 邢博越及其一致行动人杜玲、杨蓓签订了《股权转让协议书》，杜玲、杨蓓拟通过协议转让的方式分别 将各自持有的公司10,974,247股（占公司总股本的2.94%）、10,545,559股（占公司总股本的2.83%）， 合计21,519,806股（占公司总股本的5.77%）转让予邢博越。邢博越承诺在上述股权转让过户完成之日 起12个月内不减持所持有的公司股份。 本次协议转让系公司控股股东、实际控制人邢博越及其一致行动人之间内部转让，其合计持股比例、数 量和表决权未发生变化。不涉及向市场减持，不触及要约收购，不会导致公司控股股东及实际控制人发 生变化。本次协议转让前，邢博越持有公司73,272,546股（占公司总股本的19.63%），邢博越及其一致 行动人合计持有公司94,792,352股（占公司总股本的25.40%）。本次协议转让后，邢博越持有公司 94,792,352股（占公司总股本的25.40%），杜玲、杨蓓将不再持有公司股份。 ...

智通财经APP讯，金花股份(600080.SH)公告，公司控股股东、实际控制人邢博越及其一致行动人杜 玲、杨蓓签订了《股权转让协议书》，杜玲、杨蓓拟通过协议转让的方式将合计2151.98万股(占公司总 股本的5.77%)转让予邢博越。邢博越承诺在上述股权转让过户完成之日起12个月内不减持所持有的公司 股份。本次协议转让系公司控股股东、实际控制人邢博越及其一致行动人之间内部转让，其合计持股比 例、数量和表决权未发生变化。本次协议转让后，杜玲、杨蓓将不再持有公司股份。 ...

每经AI快讯，金花股份（SH 600080，收盘价：8.62元）11月24日晚间发布公告称，2025年11月24日， 金花企业（集团）股份有限公司控股股东、实际控制人邢博越及其一致行动人杜玲、杨蓓签订了《股权 转让协议书》，杜玲、杨蓓拟通过协议转让的方式分别将各自持有的公司约1097万股（占公司总股本的 2.94%）、约1055万股（占公司总股本的2.83%），合计约2152万股（占公司总股本的5.77%）转让予邢 博越。邢博越承诺在上述股权转让过户完成之日起12个月内不减持所持有的公司股份。本次协议转让系 公司控股股东、实际控制人邢博越及其一致行动人之间内部转让，其合计持股比例、数量和表决权未发 生变化。不涉及向市场减持，不触及要约收购，不会导致公司控股股东及实际控制人发生变化。 截至发稿，金花股份市值为32亿元。 每经头条（nbdtoutiao）——大鹏工业战略配售"肥"了自家人！认购价9元，上市首日涨到118元，实控 人和亲哥哥凭配售一天浮盈2492万元 （记者 曾健辉） 2024年1至12月份，金花股份的营业收入构成为：医药工业占比99.89%，医药商业占比0.14%，酒店业 占比0.03%，内部抵销 ...

Core Points - The announcement reveals that the controlling shareholder and actual controller of Jinhua Co., Ltd. (stock code: 600080), Xing Boyue, along with his concerted actors Du Ling and Yang Bei, have signed a share transfer agreement [1] - Du Ling and Yang Bei plan to transfer a total of 21.52 million shares, which accounts for 5.77% of the company's total share capital, to Xing Boyue [1] - The share transfer is an internal transfer among the controlling shareholder and his concerted actors, and there will be no change in the total shareholding ratio, quantity, or voting rights [1] Summary by Sections - **Share Transfer Details** - Du Ling will transfer 10.97 million shares (2.94% of total share capital) - Yang Bei will transfer 10.55 million shares (2.83% of total share capital) - The total shares transferred amount to 21.52 million [1] - **Commitment on Shareholding** - Xing Boyue has committed not to reduce his shareholding within 12 months after the completion of the share transfer [1]

金花企业（集团）股份有限公司 简式权益变动报告书 金花企业（集团）股份有限公司 简式权益变动报告书 上市公司名称：金花企业（集团）股份有限公司 股票上市地点：上海证券交易所 股票简称：金花股份 股票代码：600080 信息披露义务人（一致行动人）一：杜玲 金花企业（集团）股份有限公司 简式权益变动报告书 信息披露义务人声明 一、信息披露义务人依据《中华人民共和国证券法》（以下简称"《证券法》"）、 《上市公司收购管理办法》（以下简称"《收购管理办法》"）、《公开发行证 券公司信息披露内容与格式准则第 15 号—权益变动报告书》（以下简称"准则 15 号"）及相关的法律、法规编写本报告书。 信息披露义务人（一致行动人）二：杨蓓 住所：西安市莲湖区白露湾 权益变动性质：股份减少 权益变动性质：股份在一致行动人之间转让，合计持股不变 签署日期：二〇二五年十一月 1 二、信息披露义务人签署本报告书已获得必要的授权和批准，其履行亦不违 反信息披露义务人章程或内部规则中的任何条款，或与之相冲突。 住所：西安市雁塔区太白南路三号 权益变动性质：股份减少 三、依据《证券法》、《收购管理办法》的规定，本报告书已全面披露信息 披 ...

证券代码：600080 证券简称：金花股份 公告编号：2025-046 金花企业（集团）股份有限公司 关于公司控股股东、实际控制人与一致行动人协议转 让股份的公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 2025 年 11 月 24 日，金花企业（集团）股份有限公司（以下简称"公司"） 控股股东、实际控制人邢博越及其一致行动人杜玲、杨蓓签订了《股权转让协议 书》，杜玲、杨蓓拟通过协议转让的方式分别将各自持有的公司 10,974,247 股（占 公司总股本的 2.94%）、10,545,559 股（占公司总股本的 2.83%），合计 21,519,806 股（占公司总股本的 5.77%）转让予邢博越。邢博越承诺在上述股权转让过户完 成之日起 12 个月内不减持所持有的公司股份。 本次协议转让系公司控股股东、实际控制人邢博越及其一致行动人之间 内部转让，其合计持股比例、数量和表决权未发生变化。不涉及向市场减持，不 触及要约收购，不会导致公司控股股东及实际控制人发生变化。本次协议转让前， 邢博越持有 ...

Market Overview - The Chinese medicine sector experienced a decline of 0.21% on November 20, with Kanghui Co., Ltd. leading the drop [1] - The Shanghai Composite Index closed at 3931.05, down 0.4%, while the Shenzhen Component Index closed at 12980.82, down 0.76% [1] Stock Performance - Notable gainers in the Chinese medicine sector included: - *ST Changyao: Closed at 2.83, up 19.92% with a trading volume of 763,900 shares and a turnover of 197 million yuan [1] - Jinhua Co., Ltd.: Closed at 69.8, up 7.15% with a trading volume of 577,400 shares and a turnover of 505 million yuan [1] - Tailong Pharmaceutical: Closed at 7.44, up 3.33% with a trading volume of 344,200 shares and a turnover of 25.2 million yuan [1] - Conversely, Kanghui Co., Ltd. saw a decline of 3.72%, closing at 22.26 with a trading volume of 27,400 shares and a turnover of 61.69 million yuan [2] Capital Flow - The Chinese medicine sector experienced a net outflow of 143 million yuan from institutional investors, while retail investors saw a net inflow of 133 million yuan [2] - Key stocks with significant capital flow included: - Jinhua Co., Ltd.: Institutional net inflow of 99.64 million yuan, retail net outflow of 79.86 million yuan [3] - Zhongsheng Pharmaceutical: Institutional net inflow of 92.18 million yuan, retail net outflow of 51.91 million yuan [3] - Tailong Pharmaceutical: Institutional net inflow of 25.82 million yuan, retail net outflow of 31.90 million yuan [3]

Market Overview - The Chinese medicine sector rose by 0.39% on November 12, with Zhongsheng Pharmaceutical leading the gains [1] - The Shanghai Composite Index closed at 4000.14, down 0.07%, while the Shenzhen Component Index closed at 13240.62, down 0.36% [1] Top Performers - Zhongsheng Pharmaceutical (002317) closed at 23.38, up 10.02% with a trading volume of 1.3442 million shares [1] - Panlong Pharmaceutical (002864) closed at 35.64, up 10.00% with a trading volume of 162,700 shares [1] - Te Yi Pharmaceutical (002728) closed at 13.41, up 5.09% with a trading volume of 1.6884 million shares [1] - Other notable gainers include Jiu Zhi Tang (000989) up 4.99% and Jin Hua Co. (600080) up 4.93% [1] Underperformers - Yiling Pharmaceutical (002603) closed at 20.01, down 2.25% with a trading volume of 668,600 shares [2] - Weikang Pharmaceutical (300878) closed at 28.72, down 1.98% with a trading volume of 99,900 shares [2] - Kangmei Pharmaceutical (600518) closed at 2.09, down 1.42% with a trading volume of 2.9625 million shares [2] Capital Flow - The Chinese medicine sector saw a net inflow of 196 million yuan from institutional investors, while retail investors contributed a net inflow of 80.93 million yuan [2] - Speculative funds experienced a net outflow of 277 million yuan [2] Individual Stock Capital Flow - Zhongsheng Pharmaceutical had a net inflow of 4.03 billion yuan from institutional investors, but a net outflow of 2.13 billion yuan from speculative funds [3] - Tongrentang (600085) saw a net inflow of 1.22 billion yuan from institutional investors, with a net outflow of 508.17 million yuan from speculative funds [3] - Other stocks like Pian Zai Huang (600436) and Dong E E Jiao (000423) also experienced significant net inflows from institutional investors [3]